Moataz Reda

936 total citations · 1 hit paper
21 papers, 766 citations indexed

About

Moataz Reda is a scholar working on Biomedical Engineering, Molecular Biology and Oncology. According to data from OpenAlex, Moataz Reda has authored 21 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Biomedical Engineering, 9 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Moataz Reda's work include Nanoplatforms for cancer theranostics (8 papers), Nanoparticle-Based Drug Delivery (6 papers) and RNA Interference and Gene Delivery (5 papers). Moataz Reda is often cited by papers focused on Nanoplatforms for cancer theranostics (8 papers), Nanoparticle-Based Drug Delivery (6 papers) and RNA Interference and Gene Delivery (5 papers). Moataz Reda collaborates with scholars based in United States, Thailand and Canada. Moataz Reda's co-authors include Wassana Yantasee, Worapol Ngamcherdtrakul, Shenda Gu, Joe W. Gray, Thanapon Sangvanich, David J. Castro, Jingga Morry, Daniel S. Bejan, Zhi Hu and Shaun M. Goodyear and has published in prestigious journals such as Advanced Materials, Nature Communications and PLoS ONE.

In The Last Decade

Moataz Reda

20 papers receiving 763 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

2022 140 citations Moataz Reda, Worapol Ngamcherdtrakul et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Moataz Reda United States	13	399	280	228	175	132	21	766
Seungho Lim South Korea	14	392 1.0×	444 1.6×	273 1.2×	112 0.6×	140 1.1×	18	863
Shabnum Patel United States	14	455 1.1×	227 0.8×	251 1.1×	273 1.6×	249 1.9×	27	1.1k
Hanhee Cho South Korea	16	328 0.8×	401 1.4×	304 1.3×	240 1.4×	193 1.5×	30	818
Mikhail Durymanov Russia	15	436 1.1×	310 1.1×	247 1.1×	132 0.8×	65 0.5×	39	904
Andrew Satterlee United States	13	628 1.6×	425 1.5×	369 1.6×	200 1.1×	161 1.2×	29	1.2k
Yu-Cheng Tseng United States	8	604 1.5×	303 1.1×	254 1.1×	130 0.7×	212 1.6×	8	927
Jiwoong Choi South Korea	14	281 0.7×	497 1.8×	259 1.1×	226 1.3×	215 1.6×	24	844
Di Jing China	14	319 0.8×	332 1.2×	270 1.2×	112 0.6×	78 0.6×	35	780
Dennis Huang United States	10	244 0.6×	455 1.6×	303 1.3×	133 0.8×	117 0.9×	14	763
Bongseo Choi United States	16	395 1.0×	290 1.0×	135 0.6×	165 0.9×	295 2.2×	26	974

Countries citing papers authored by Moataz Reda

Since Specialization

Citations

This map shows the geographic impact of Moataz Reda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moataz Reda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moataz Reda more than expected).

Fields of papers citing papers by Moataz Reda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moataz Reda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moataz Reda. The network helps show where Moataz Reda may publish in the future.

Co-authorship network of co-authors of Moataz Reda

This figure shows the co-authorship network connecting the top 25 collaborators of Moataz Reda. A scholar is included among the top collaborators of Moataz Reda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moataz Reda. Moataz Reda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Angelis, Maria Teresa De, Antonia Rizzuto, Moataz Reda, et al.. (2025). Distinctive chromosomal, mutational and transcriptional profiling in colon versus rectal cancers. Journal of Translational Medicine. 23(1). 869–869.

Reda, Moataz, et al.. (2025). Abstract A052: Development of PD-L1 and STING-targeted nanoparticles for lung cancer treatment. Cancer Immunology Research. 13(2_Supplement). A052–A052. 2 indexed citations

Wang, Ruijie, et al.. (2023). Nanotechnology Applications in Breast Cancer Immunotherapy. Small. 20(41). e2308639–e2308639. 16 indexed citations

Reda, Moataz, et al.. (2023). Abstract 5119: Nano-immunotherapy targeting PD-L1, PLK1, and TLR9 for treatment of non-small cell lung cancer. Cancer Research. 83(7_Supplement). 5119–5119. 2 indexed citations

Ngamcherdtrakul, Worapol, Moataz Reda, Ruijie Wang, et al.. (2023). Abstract 3229: Triggering anti-tumor immune response with a nanotherapeutic that targets TLR9 and STAT3 pathways. Cancer Research. 83(7_Supplement). 3229–3229. 1 indexed citations

Ngamcherdtrakul, Worapol, Daniel S. Bejan, William Cruz‐Muñoz, et al.. (2022). Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis. Small. 18(11). e2107550–e2107550. 42 indexed citations

Reda, Moataz, Worapol Ngamcherdtrakul, Molly A. Nelson, et al.. (2022). Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nature Communications. 13(1). 4261–4261. 140 indexed citations breakdown →

Ngamcherdtrakul, Worapol, Daniel S. Bejan, William Cruz‐Muñoz, et al.. (2022). Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis (Small 11/2022). Small. 18(11). 1 indexed citations

Ngamcherdtrakul, Worapol, Moataz Reda, Molly A. Nelson, et al.. (2021). In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response. Advanced Materials. 33(31). e2100628–e2100628. 61 indexed citations

10.

Reda, Moataz, et al.. (2020). Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials. Radiotherapy and Oncology. 150. 225–235. 17 indexed citations

11.

Reda, Moataz, Worapol Ngamcherdtrakul, Shenda Gu, et al.. (2019). PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Letters. 467. 9–18. 56 indexed citations

12.

Ngamcherdtrakul, Worapol, Jingga Morry, Thanapon Sangvanich, et al.. (2019). Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model. Scientific Reports. 9(1). 709–709. 6 indexed citations

13.

Gu, Shenda, Worapol Ngamcherdtrakul, Moataz Reda, et al.. (2018). Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS ONE. 13(6). e0198141–e0198141. 19 indexed citations

14.

Ngamcherdtrakul, Worapol, Thanapon Sangvanich, Moataz Reda, et al.. (2018). Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery. International Journal of Nanomedicine. Volume 13. 4015–4027. 55 indexed citations

15.

Morry, Jingga, Worapol Ngamcherdtrakul, Shenda Gu, et al.. (2017). Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform. Molecular Cancer Therapeutics. 16(4). 763–772. 51 indexed citations

16.

Ngamcherdtrakul, Worapol, David J. Castro, Shenda Gu, et al.. (2016). Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treatment Reviews. 45. 19–29. 23 indexed citations

17.

Gu, Shenda, Zhi Hu, Worapol Ngamcherdtrakul, et al.. (2016). Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget. 7(12). 14727–14741. 38 indexed citations

18.

Morry, Jingga, Worapol Ngamcherdtrakul, Shenda Gu, et al.. (2015). Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials. 66. 41–52. 56 indexed citations

19.

Ngamcherdtrakul, Worapol, Jingga Morry, Shenda Gu, et al.. (2015). Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2⁺ Breast Cancer. Advanced Functional Materials. 25(18). 2646–2659. 167 indexed citations

20.

Ngamcherdtrakul, Worapol, Jingga Morry, Shenda Gu, et al.. (2015). Cancer Nanomedicine: Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2⁺ Breast Cancer (Adv. Funct. Mater. 18/2015). Advanced Functional Materials. 25(18). 2629–2629. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact